Cargando…

Efficacy Analysis of Combining Sintilimab with Neoadjuvant Chemotherapy in Treating Middle and Advanced Rectal Cancer Based on Big Data

OBJECTIVE: To analyze the efficacy of combining sintilimab with neoadjuvant chemotherapy in treating middle and advanced rectal cancer based on big data. METHODS: According to the inclusion and exclusion criteria, 43 patients with middle and advanced rectal cancer, who were treated with sintilimab a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yifei, Fei, Jiandong, Zheng, Yanan, Li, Ping, Ren, Xiaodong, An, Yongzhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507646/ https://www.ncbi.nlm.nih.gov/pubmed/36157237 http://dx.doi.org/10.1155/2022/8675587

Ejemplares similares

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
por: Liu, Linlin, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
por: Papaccio, Federica, et al.
Publicado: (2020)

Timing of additional neoadjuvant chemotherapy in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision
por: He, Fang, et al.
Publicado: (2022)

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review
por: Yin, Cunli, et al.
Publicado: (2023)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer
por: Tokuhara, Katsuji, et al.
Publicado: (2022)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study
por: Li, Xiaofen, et al.
Publicado: (2022)

Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer
por: Xie, Jiejie, et al.
Publicado: (2022)

Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy
por: Yoo, Ri Na, et al.
Publicado: (2019)

Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)
por: Zhang, Zhenyang, et al.
Publicado: (2021)

A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)
por: Duan, Hongtao, et al.
Publicado: (2021)

Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series
por: Fan, Bo-Shi, et al.
Publicado: (2022)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
por: He, Lei, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy
por: Chang, Hui, et al.
Publicado: (2020)

Predicting development of distant metastases and long-term outcome of locally advanced rectal cancer treated with neoadjuvant chemotherapy and radiation
por: Aschele, Carlo, et al.
Publicado: (2022)

Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade
por: He, Le, et al.
Publicado: (2022)

Investigating the association between radiological images and the pathology of rectal cancer treated with neoadjuvant chemotherapy
por: Morohashi, Satoko, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial
por: Shao, Miner, et al.
Publicado: (2023)

The Outcome of Induction Chemotherapy, Followed by Neoadjuvant Chemoradiotherapy and Surgery, in Locally Advanced Rectal Cancer
por: Yaghobi Joybari, Ali, et al.
Publicado: (2021)

Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?
por: Long Roche, Kara, et al.
Publicado: (2020)

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
por: Wei, Jia, et al.
Publicado: (2023)

Resolving the tissue response to neoadjuvant chemotherapy in rectal cancer
por: Shyer, Justin A., et al.
Publicado: (2023)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Predicting outcomes for locally advanced rectal cancer treated with neoadjuvant chemoradiation with CT-based radiomics
por: Wang, Fuqiang, et al.
Publicado: (2022)

Tumor Volume Reduction Rate Predicts Pathologic Tumor Response of Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemotherapy alone: Results from a Prospective Trial
por: Xiao, Jian, et al.
Publicado: (2015)

Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally‐advanced rectal cancer
por: Hardiman, Karin M., et al.
Publicado: (2019)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

Prognostic Value of Interval Between the Initiation of Neoadjuvant Treatment to Surgery for Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemotherapy, Radiotherapy and Definitive Surgery
por: Wan, Xiang-Bo, et al.
Publicado: (2020)

Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer
por: Liang, Xiaoyan, et al.
Publicado: (2021)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma—A Report of Two Cases
por: Mei, Xinkuan, et al.
Publicado: (2022)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Li, Yi, et al.
Publicado: (2016)

Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study
por: Ding, Ping’an, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b99t2lenjsl20okg72n5qjgagg